Announcement • May 18
Sybleu Inc. announced delayed 10-Q filing On 05/16/2024, Sybleu Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Announcement • Apr 19
Worldwide Holdings, LLC acquired 58.5% stake in Sybleu Inc. (OTCPK:SYBE) from Joseph Vaini and Harry Lander for $1. Worldwide Holdings, LLC acquired 58.5% stake in Sybleu Inc. (OTCPK:SYBE) from Joseph Vaini and Harry Lander for $1 on April 15, 2024. Under the terms of agreement, Worldwide Holdings acquired certain outstanding notes of Sybleu from certain noteholders for an aggregate consideration of $458,499 and acquired in aggregate 6,210,790 shares of Sybleu's common stock from Joseph Vaini and Harry Lander for an aggregate consideration of $1.00. Joseph Vaini resigned as Director of Sybleu and Jeremy Davey, Laman Milner, and John Clark were appointed as directors. Upon closing of the transaction, Jeremy Davey was appointed as Chairman of the Board of Directors and Chief Executive Officer, Laman Milner was appointed as President, and John Clark was appointed as Secretary. Dane Johansen of Parr Brown Gee & Loveless PC acted as legal advisor to Worldwide Holdings.
Worldwide Holdings, LLC completed the acquisition of 58.5% stake in Sybleu Inc. (OTCPK:SYBE) on April 15, 2024. Announcement • Jun 28
Sybleu Inc. Obtains Exclusive License for Artificial Intelligence/ Machine Learning Small Molecule Drug Design Engine Sybleu Inc. is preparing to begin advancing small molecule drug therapies for animal and human health. Because Sybleu has developed a corporate strategy centered around acquiring intellectual property and forging strategic partnerships to advance technologies to market, the company has been carefully screening potential in-licensing opportunities as it builds its portfolio. The company has identified a technology owned by DYO Biotechnologies, Pty Ltd. which is centered around artificial intelligence and machine learning and that has already been used to create a drug currently in clinical trials. Specifically, this technology consists of an artificial intelligence/machine learning engine designed to utilize existing chemical library structures in an integrated model to predict highly specific and sensitive novel chemical structures for molecular targets. Any future small molecule drugs that Sybleu in-licenses or develops can be rapidly improved and moved forward in the development process using this intellectual property. Under the terms of the license agreement, Sybleu will have exclusive, worldwide rights to the intellectual property and will own any intellectual property that DYO will be contracted to develop. Furthermore, Sybleu will have the right to sublicense the technology. 
